


Pembrolizumab KEYNOTE-716

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Pembrolizumab KEYNOTE-716

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Skin Cancers

Therapeutic Indication: FDA therapeutic indication: adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC following complete resection. EMA therapeutic indication: adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB, IIC or III melanoma and who have undergone complete resection

Experimental Arm: Pembrolizumab

Control Arm: Placebo



